Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Appendix B Monday, July 16, 2001 Meeting Agenda IMMUNIZATION SAFETY REVIEW COMMITTEE Thimerosal-Containing Vaccines and Neurodevelopmental Outcomes Public Meeting The Charles Hotel Conant Wadsworth B Conference Room One Bennett Street Cambridge, MA PUBLIC SESSION 8:00-8:10 a.m. Welcome and Introductions Marie McCormick, M.D., Sc.D. Chair, Immunization Safety Review Committee 8:10-8:30 a.m. Risk Assessment of Thimerosal in Childhood Vaccines Leslie K. Ball, M.D. Division of Vaccines and Related Product Applications Office of Vaccines Research and Review Center for Biologics Evaluation and Research Food and Drug Administration 8:30-9:00 a.m. History of Thimerosal Concern and Comparative Policy Actions Gary L. Freed, M.D. The Percy and Mary Murphy Professor of Pediatrics and Child Health Delivery Director, Division of General Pediatrics Professor of Health Management and Policy University of Michigan 107
108 IMMUNIZA TION SAFETY RE VIE W Margie Andreae, M.D. Associate Director for Clinical Services Division of General Pediatrics University of Michigan 9:00-9:35 a.m. Biologic Plausibility and Planned Research Jane M. El-Dahr, M.D. Head, Section of Pediatric Allergy, Immunology, Rheumatology Tulane University Health Sciences Center David S. Baskin, M.D. Professor of Neurosurgery Baylor College of Medicine 9:35-10:00 a.m. The Role of Heavy Metals in Autism Jeffrey Bradstreet, M.D. Director of Research The International Autism Research Center 10:15-10:45 a.m. Pharmacokinetic Modeling of Hair Mercury Levels from Thimerosal David Brown, Sc.D. Toxicologist and Independent Consultant Connecticut 10:45 -11:30 a.m. Vaccine Safety Datalink (VSD) Screening Study and Fol- low-Up Analysis with Harvard Pilgrim Data Thomas Verstraeten, M.D., M.Sc. EIS Officer, National Immunization Program Centers for Disease Control and Prevention 11:30-12:00noonProtocol for National Immunization Program Study on Thimerosal Paul Stehr-Green, Dr.P.H., M.P.H. Associate Professor of Epidemiology University of Washington School of Community Medicine and Public Health William Thompson, Ph.D. For Q&A period only Epidemiologist, National Immunization Program Centers for Disease Control and Prevention
APPENDIXB: MEETING AGENDA 1:00 -1 :30 p.m. Seychelles Islands Study Gary Myers, M.D. Professor of Neurology and Pediatrics University of Rochester School of Medicine and Dentistry 1 :30-2:00 p.m. Faroe Islands Study Philippe Grandjean, M.D., D.M.Sc. Institute of Community Health Odense University, Denmark 2:00-2:30 p.m. In Vitro Studies of Thimerosal Toxicity Boyd E. Haley, Ph.D. Chairman and Professor, Department of Chemistry University of Kentucky 2:30-3:00 p.m. Comparative Toxicology of Ethyl and Methyl Mercury George Lucier, Ph.D. Former Director, Environmental Toxicology Program National Institute for Environmental Health Sciences 3:15-3:30 p.m. Rising Incidence of Autism: Association with Thimerosal Mark F. Blaxill, M.B.A. Autism Society of America, Massachusetts Chapter 3:30-3:45 p.m. NIH Studies on Thimerosal Polly Sager, Ph.D. National Institute of Allergy and Infectious Diseases National Institutes of Health 3 :45-4: 10 p.m. Wrap-Up Commentary on Thimerosal Risk From the Perspective of a Developmental Toxicologist George Lambert, M.D. Environmental and Occupational Health Sciences Institute Robert Wood Johnson Medical School 4:10-4:35 p.m. Wrap-up Commentary on Thimerosal Risk From the Perspective of a Pediatric Vaccinologist Neal Halsey, M.D. Professor and Director Division of Disease Control Department of International Health The Johns Hopkins University 4:35-5:00 p.m. Public comment period 109